Description

Wegovy for weight loss

Wegovy for weight loss (semaglutide) injection is a prescription medicine used for weight loss in obese adults and teenagers, or overweight adults with other weight-related medical issues. Wegovy works by regulating appetite and reducing calorie intake, leading to weight loss and helping with weight management.

Wegovy for weight loss belongs to the class of drugs called GLP-1 receptor agonists. GLP-1 receptor agonists are a manufactured version of GLP-1, a naturally occurring hormone in the body that acts in several areas in the brain to regulate food intake. When Wegovy is administered, it activates the GLP-1 receptors in the brain. This lowers appetite, reducing the calories consumed, and leading to weight loss.

This medicine should be used together with a decreased-calorie meal plan and increased physical activity to help weight management.

Wegovy is given as an injection under the skin (subcutaneous injection) once a week.

Wegovy for weight loss is an FDA-approved anti-obesity medicine to be used by people 12 years and older for chronic weight management when used together with a reduced-calorie diet and increased physical activity.

Wegovy is indicated for use in:

Adults:

• Obese (BMI of 30 kg/m2 or greater)
• Overweight (BMI of 27 kg/m2 or greater) and have medical problems (e.g.high blood pressure, type 2 diabetes, or high cholesterol) due to your weight.

Pediatric (12 years and older):

• Obese (initial BMI 95th percentile or greater for age and sex)

Wegovy for weight losscontains semaglutide which is the same active ingredient in Ozempic and Rybelsus, therefore these products should not be used together. Ozempic (subcutaneous weekly injection) and Rybelsus (once-a-day tablet) are used lower blood sugar levels for type two diabetic patients. Ozempic is also used to lower the risk of major cardiovascular events for some type 2 diabetic patients.

Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath. In studies with rodents, Wegovy and medicines that work like Wegovy caused thyroid tumors, including thyroid cancer. It is not known if this medicine will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.

You should not use this medicine if you have tumors in your glands called multiple endocrine neoplasia type 2  (MEN 2), or a personal or family history of medullary thyroid cancer (MTC).

The dose starts low and escalates to minimize gastrointestinal side effects.

Initial Dose Escalation Schedule for patients aged 12 years and older:

• Weeks 1 through 4 (month one): 0.25 mg subcutaneously once a week
• Weeks 5 through 8 (month two): 0.5 mg subcutaneously once a week
• Weeks 9 through 12 (month three): 1 mg subcutaneously once a week
• Weeks 13 through 16 (month four): 1.7 mg subcutaneously once a week

Maintenance Dose:

• Week 17 and onward: 2.4 mg subcutaneously once a week. See additional notes below about maintenance dosing.

Maintenance Dosage Adult Patients. The maintenance dosage is 2.4 mg injected subcutaneously once weekly. If the patient does not tolerate the maintenance 2.4 mg once-weekly dosage, then the dosage can be temporarily decreased to 1.7 mg once a week, for a maximum of 4 weeks. After four weeks, the dose should be increased to the maintenance 2.4 mg once-weekly dosage. Discontinue this medicine if the patient cannot tolerate the 2.4 mg dosage.

Pediatric Patients Aged 12 Years and Older. The recommended maintenance dosage of Wegovy for weight loss is 2.4 mg injected subcutaneously once weekly. If the patient does not tolerate the maintenance 2.4 mg once-weekly dosage, the maintenance dosage may be reduced to 1.7 mg once weekly. Discontinue this medicine if the patient cannot tolerate the 1.7 mg dose.

Ozempic for weight loss, Saxenda Weight Loss, Saxenda for weight loss, Trulicity for weight loss